Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 6/20 | 0.75 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | ACLY | P53396 | 3/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12570805 | 0.91 | METAP2 (0.86) | METAP2MCL1CYP2C9CYP1A2ACLY | |
| SCHEMBL16495860 | 0.86 | METAP2 (0.73) | METAP2MCL1ACLYKDM1A | |
| SCHEMBL12200769 | 0.86 | METAP2 (0.71) | METAP2MCL1CYP2C9CYP1A2KDM1A | |
| SCHEMBL9164473 | 0.86 | METAP2 (0.85) | METAP2CYP2C9CYP1A2ACLYLMNA | |
| SCHEMBL19083016 | 0.86 | METAP2 (1.00) | METAP2MCL1CYP2C9CYP1A2KDM1A | |
| Hydrochloric Acid SCHEMBL7409073 | 0.85 | METAP2 (0.82) | METAP2CYP2C9CYP1A2ACLYLMNA | |
| SCHEMBL14087834 | 0.85 | METAP2 (0.70) | METAP2MCL1CYP2C9CYP1A2LMNA | |
| SCHEMBL3512984 | 0.85 | CYP2C9 (0.90) | METAP2MCL1CYP2C9CYP1A2LMNA | |
| SCHEMBL2009251 | 0.84 | METAP2 (1.00) | METAP2MCL1CYP2C9CYP1A2LMNA | |
| SCHEMBL3980105 | 0.83 | METAP2 (0.81) | METAP2MCL1CYP2C9CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294853-A1 | Bis Aromatic Compounds for Use in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294853-A1 | Bis Aromatic Compounds for Use in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | METAP2 1475/4885MCL1 2970/4885CYP2C9 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.